JPRN-jRCT2080222621已完成1 期
Extension Study of WT4869 in Patients with Myelodysplastic Syndromes (MDS)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
The aim of this study was to evaluate safety and efficacy of long-term administration of WT4869 in MDS patients.The dose was allowed to be increased by one step to 600 mcg per body for each dose after the second dose in this study. The dose was increased in 4 patients.The dose was increased to 600 mcg per body in 3 patients, which was the highest dose, but there were no major safety concerns. Hematologic response occurred in 3 of 6 patients. Two of these patients responded in the study.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who completed Phase I/II study
排除标准
- •Patients with concomitant infections of Grade 3 or greater
研究者
相似试验
终止
1 期
Phase I/II study of WT4869 for MDSMyelodysplastic syndromesJPRN-jRCT2080221337Sumitomo Dainippon Pharma Co., Ltd.26
终止
3 期
Safety Study of MT-4666 in Subjects With Alzheimer's DiseaseAlzheimer's DiseaseNCT02327182Mitsubishi Tanabe Pharma Corporation117
撤回
2 期
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)Mantle-CellLymphomaNCT01244009Tesaro, Inc.
已完成
2 期
Long-Term Study of MP-214 in Patients With SchizophreniaSchizophreniaNCT01626872Tanabe Pharma Corporation254
已完成
3 期
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseCushings DiseaseNCT02180217Novartis Pharmaceuticals137